Fig. 4: SOF10 shows antifibrotic activity and ameliorates kidney function in kidney models.

a, b Kidney antifibrotic activity was evaluated in UUO mice. a The mice were treated with either isotype control or SOF10 (mFc) one day before UUO surgery. b Antifibrotic activity was evaluated by measuring Serpine1, Col1a1, and Col3a1 mRNA in the kidney. RNA was extracted from the kidney at necropsy and gene expression was analyzed by quantitative RT–PCR. Kidney fibrosis was evaluated by measuring hydroxyproline levels. N = 4 in the sham control group, N = 10 in the disease control group, and N = 10 in the SOF10 (mFc) treatment groups. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; ns: P > 0.05; unpaired two-tailed Student’s t test. #P < 0.05, ##P < 0.01, ###P < 0.001, ####P < 0.0001; ns: P > 0.05; Dunnett’s multiple comparisons test. The data are presented as the means ± SEMs. c–h Kidney fibrosis and amelioration of kidney dysfunction were evaluated in Col4A3 KO mice. c The mice were subcutaneously injected with either the isotype control or SOF10 (mFc) twice a week from 14 to 20 weeks of age. d Kidney function was evaluated by measuring plasma creatinine, UN (BUN), and cystatin C (CysC) levels at 21 weeks of age. e Antifibrotic activity was evaluated by measuring Serpine1, Col1a1, and Col3a1 mRNA and measuring hydroxyproline levels in the kidney. RNA was extracted from kidney at necropsy and gene expression was analyzed by quantitative RT–PCR. f–h Interstitial fibrosis and glomerulosclerosis were evaluated by histopathological analysis. N = 4 in the wild-type group, N = 12 in the disease control group and N = 14 in the SOF10 (mFc) treatment group. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; ns: P > 0.05; unpaired two-tailed Student’s t test. The data are presented as the means ± SEMs. Fibrosis areas (asterisks); glomerulosclerosis (arrowheads). HE and Sirius red staining, bar = 100 μm. PAM staining, bar = 50 μm. SR sirius red.